FAQs about Rystiggo

Category: Rystiggo

The U.S. Food and Drug Administration (FDA) approved Rystiggo in June 2023 as a treatment for adults with generalized myasthenia gravis (gMG) who have antibodies against the acetylcholine receptor or muscle-specific kinase — the two most common types of disease-driving antibodies. The approval made Rystiggo the first therapy available for the two most common gMG subtypes.

Category: Rystiggo

In the MycarinG clinical trial that supported Rystiggo’s approval, patients with generalized myasthenia gravis (gMG) experienced improvements in measures of disease severity as early as eight days after starting treatment. However, each patient is unique and may respond differently to treatment. All are advised to talk with their healthcare team to better understand how Rystiggo can help in their particular case.

Category: Rystiggo

Neither hair loss nor weight gain have been reported in clinical trials as side effects of Rystiggo. It is recommended patients speak with their healthcare team if they experience any unanticipated side effects while on the medication.

Category: Rystiggo

Rystiggo has not been rigorously studied in pregnant people, but animal data suggests it may cause fetal harm. Patients who are pregnant or planning to become pregnant should discuss this topic with their healthcare providers.

Category: Rystiggo

It is unclear whether Rystiggo can affect a person’s ability to drive and use machinery. Patients should be careful before attempting to drive or use any machinery until they know how the therapy affects them. Patients planning to start taking Rystiggo are advised to talk with their healthcare team to learn more about how the treatment could affect their ability to perform certain activities, including driving.